Original research drug pricing or cancellation alone

Nanfang Daily reporter Newsiyan November 30, the National Development and Reform Commission issued a notice, decided to start on December 12 to lower the price of some individual drugs, the highest retail price, involving antibiotics, cardio-cerebral blood vessels, such as 17 major categories of drugs, the average price reduction of up to 19%. And the industry's concern is that the NDRC canceled a number of separate pricing of drugs, the market has been rumored that the drug "separate pricing" or will end.　　Nanfang daily reporters to prove that the industry generally agreed that the impact of the adjustment is limited, but the transfer of the adjustment means quite obvious. In fact, the original research drugs and the existence of individual pricing is to guide the drug innovation, not the price of drugs to pull high, the key is the setting of the market is reasonable, after all, drug prices and drug innovation should be the industry in parallel with the development trend.　　"A pharmaceutical analyst who declined to be named has made the above comments to reporters," he said. It is the first time that the NDRC has cut prices for separately priced drugs.　　"CIC consultant pharmaceutical industry researcher Guofan told reporters, and the NDRC adjusted the price of the biggest difference is that the adjustment for the" separate pricing "drugs.　　In fact, because of the independent pricing of the original research drugs for foreign investment, joint ventures production, there has been a lot of rumors that the "NDRC wants to abolish foreign drug supranational treatment." In this respect, China Foreign Investment Enterprise Association Pharmaceutical Research and Development Industry Committee yesterday formally submitted a statement to our correspondent said: "To adjust the price of the original research drug prices will inhibit the industry quality system input, not conducive to China's pharmaceutical market and the healthy development of the pharmaceutical industry." Zuo, government affairs and Media Communications director of the Department, explained, "The original research drug in research and development, clinical validation, drug alert, imported raw materials, management costs of huge investment." If the overall pharmaceutical price level to imitation as a reference, will eventually inhibit the industry quality management system input, not conducive to drug quality improvement and the overall industry's healthy development.　　"But the domestic call for the abolition of" original research medicine "alone is not two days. "Separate pricing, especially the original research drug pricing has been unreasonable for too long, and generic drug gap is too large, our association and domestic enterprises have made many comments." "China Pharmaceutical Enterprise Management Association president Yu said that the original research drug pricing policy has been most local domestic drug companies criticized," if it is too outrageous to drop. "Insiders said, November 23, the National Development and Reform Commission formally convened a number of mainstream pharmaceutical companies, the individual pricing policy adjustment scheme small scope for advice.　　Sources said that the development and Reform Commission to speed up the adjustment of the price of the original research is a direct reason is that recently, a "national basic drug foreign investment in the original research drug pricing and domestic drugs unified pricing table" widely circulated in the network, the list of 9 foreign-funded original research drugs and the same product domestic medicine, the average price is higher than 1311%. Or will be good domestic pharmaceutical companies under the November 29 issued by the National Development and Reform Commission on the reduction of ceftriaxone and other parts of the drug mostThe high retail price notice will reduce the highest retail price of 174 separate priced drugs, such as ceftriaxone. The specific price reduction list provided by the NDRC does not have a percentage of the price per drug.　　And the news that the price adjustment and Reform Commission originally planned to be between 30%-40%, the current 19% of the average reduction in intensity has been greatly diminished. Although there is no scale list, but the NDRC cited the proportion of specific drug prices, Sino-American Pharmaceutical Co., Ltd. Shanghai, the production of Captopril (commodity name: Open Bo Tong, 12.5mgx20 film) from 34 yuan to 22.1 yuan, the decline of 35%; Roche's Ceftriaxone (product name: Roche, 1g injection) Price from 93.8 yuan to 65.7 yuan, the decline of 30%.　　Merck produced by Simvastatin and the Southwest Pharmaceutical Co., Ltd. produced cefazolin sodium injections, such as drugs are simply canceled separately priced. Roche spokesman Cao Shu, in an interview, avoided the effect of the adjustment on Roche, but said that the country's policy adjustment they "have no way", can only comply with the implementation, do not know the future direction of the policy, and Roche will insist on continuing to promote drug innovation, " I believe that the provision of better quality drugs is always the competition in this industry. "Analysts say the impact on foreign companies is not that big in terms of the current round of regulation alone. "The first is a limited variety of only 16 species, and not fully spread out." Second, take a closer look at the list, you can find that the adjustment of the drugs are mostly ' old medicine ', the domestic generic drugs have been very much, and the effect is good. Most of the drugs that have been canceled have been discontinued, and the impact is not so great for these companies. "CIC consultant Medicine industry researcher Guofan also said that the original research drug has a brand advantage, if the price of the same generic drug prices after the difference is not large, the original price for the choice of generic drug patients may switch to buy the original research medicine." "As a result, the profit margins lost by the original research drugs may be made up or even enlarged by the market that seizes generic drugs." "is slightly June management consultant Liujin also think," the original research drug price, the cost of space to reduce, not conducive to the end of the promotion of domestic-related generic drug companies, or will be favorable. And China's pharmaceutical industry in the long term has a good growth, the drug companies in fact have the opportunity.　　"Pharmaceutical innovation and drug price reduction parallel to the original research drug" separate pricing "controversy has not been a day, the reason will again arouse the debate, because this is related to the next step of the regulation of drug prices. will be introduced in the recent "Drug price management measures (draft)" has been abolished the "original research drug" concept, and asked the original research drug prices periodically.　　Compared with the current China's 2000-year version of the "Drug pricing method" is only a normative document, the "measures" will be issued in the form of the National Development and Reform Commission, will be the next stage of China's drug pricing mechanism to clarify the thinking. At the end of October this year, the National Development and Reform Commission Price Division deputy Director of pharmaceutical prices Royan in Guangzhou clearsaid that the NDRC will gradually reduce the current original research and imitation of the price gap between; for the new listing of the original medicine, will be with generic drug prices generally linked to the listed generic drugs, in line with national policy support, or regulatory bodies, authoritative bodies to prove the quality of a clear advantage, and unified price appropriate difference,　　But the goal is to encourage domestic companies to go abroad. "The general control of basic drug prices is a major trend in the reform of medical security system, and future drug prices are the trend!" Liujin, the management consultant, said, "The general direction of the State to encourage innovation in medicine is unchanged." At present, the first imitation drug still has a certain price advantage. For the pharmaceutical industry, in response to the price of medicine, pharmaceutical companies still need to increase the research and development of new drugs, industry concentration, to achieve scale management, reduce costs, and the circulation of enterprises, to reduce circulation links, reduce the circulation costs, in order to cope with the reduction of profits caused by the compression. "" The original research medicine and the individual pricing system have their reasonable place, now unreasonable place is the identification of these drugs and the withdrawal mechanism is not sound, drug price reduction and drug innovation should be in the industry parallel development trend. "A pharmaceutical analyst, who declined to be named, also said that," the NDRC said in a 2006 ' reform proposal "that it hopes to solve the drug pricing problem by setting up a" new drug approval and price validation linkage mechanism ". "The reporter observes only cancels" the individual pricing "apparently not enough the national Food and Drug Administration The Southern Economic Research Institute released the report, the country produces the chemical most is the generic medicine, although approved the new drug quantity, but the structure is low, the technical content relatively high new class of drugs accounted for less than 10%.　　From the domestic aspect, the level of drug use is low, the ability to pay is limited, mainly using traditional PU medicine, high priced new drugs can not occupy a larger market space. In the case of statins, Pfizer's simvastatin global sales of 12.8 billion U.S. dollars, China's sales of 1.2 billion yuan. The domestic imitation of the simvastatin annual sales of only 250 million yuan.　　The lack of domestic drugs has affected the development of domestic pharmaceutical enterprises, but also to a certain extent, leading to foreign investment in the original research drugs to obtain high prices sales. Therefore, to really abolish the foreign-funded original research drugs of the supranational treatment, domestic imitation pharmaceutical enterprises should start from their own quality, through the promotion of such standards, so that more generic drugs through international certification, to the international market. Then let the foreign-funded original research drug to lose the individual pricing "high-quality" basis. and to reduce the price of medicine as one of the main objectives of the current health reform is a larger system engineering, only through the "abolition of individual pricing" is clearly not enough.